Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy.

Type I interferons in anticancer immunity. Nat Rev Immunol (2015) 1.57

Classification of current anticancer immunotherapies. Oncotarget (2014) 1.55

Trial Watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology (2014) 1.49

Trial Watch:: Oncolytic viruses for cancer therapy. Oncoimmunology (2014) 1.22

The Repurposing Drugs in Oncology (ReDO) Project. Ecancermedicalscience (2014) 1.08

Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. Oncoimmunology (2015) 1.07

Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. Oncoimmunology (2015) 1.06

Combinatorial strategies for the induction of immunogenic cell death. Front Immunol (2015) 0.98

Trial Watch: Adoptive cell transfer for anticancer immunotherapy. Oncoimmunology (2014) 0.96

Trial Watch: Toll-like receptor agonists in oncological indications. Oncoimmunology (2014) 0.96

Trial watch: Immunostimulatory cytokines in cancer therapy. Oncoimmunology (2014) 0.95

Trial Watch: Radioimmunotherapy for oncological indications. Oncoimmunology (2014) 0.91

Trial watch: Dendritic cell-based anticancer therapy. Oncoimmunology (2014) 0.90

Tumor stroma-derived factors skew monocyte to dendritic cell differentiation toward a suppressive CD14(+) PD-L1(+) phenotype in prostate cancer. Oncoimmunology (2014) 0.89

First oncolytic virus approved for melanoma immunotherapy. Oncoimmunology (2015) 0.88

Chloroquine and hydroxychloroquine for cancer therapy. Mol Cell Oncol (2014) 0.88

Non-Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy. J Thorac Oncol (2015) 0.87

Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies. Biochim Biophys Acta (2015) 0.86

Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy. Oncoimmunology (2016) 0.84

Novel immune checkpoint blocker approved for the treatment of advanced melanoma. Oncoimmunology (2014) 0.84

Checkpoint modulation--A new way to direct the immune system against renal cell carcinoma. Hum Vaccin Immunother (2015) 0.83

Trial Watch-Oncolytic viruses and cancer therapy. Oncoimmunology (2015) 0.83

Trial watch: Naked and vectored DNA-based anticancer vaccines. Oncoimmunology (2015) 0.83

Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma-An exclamation sign with a question mark. Oncoimmunology (2015) 0.82

Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using ex vivo myeloid-derived suppressor cells as a readout of therapeutic efficacy. Oncoimmunology (2014) 0.82

Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1. Immunotherapy (2015) 0.81

CD137 and CD137L signals are main drivers of type 1, cell-mediated immune responses. Oncoimmunology (2015) 0.81

Trial Watch: Immunotherapy plus radiation therapy for oncological indications. Oncoimmunology (2016) 0.81

Doubling the blockade for melanoma immunotherapy. Oncoimmunology (2015) 0.80

Isobavachalcone induces the apoptosis of gastric cancer cells via inhibition of the Akt and Erk pathways. Exp Ther Med (2015) 0.79

Enhancing Cancer Immunotherapy Via Activation of Innate Immunity. Semin Oncol (2015) 0.79

Immunotherapy of hematological cancers: PD-1 blockade for the treatment of Hodgkin's lymphoma. Oncoimmunology (2015) 0.78

STAT3 inhibition for cancer therapy: Cell-autonomous effects only? Oncoimmunology (2016) 0.78

Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium. J Immunol Res (2016) 0.77

Trial Watch-Immunostimulation with cytokines in cancer therapy. Oncoimmunology (2015) 0.77

Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. Oncoimmunology (2015) 0.77

Selection strategies for anticancer antibody discovery: searching off the beaten path. Trends Biotechnol (2015) 0.76

Advancing targeted co-stimulation with antibody-fusion proteins by introducing TNF superfamily members in a single-chain format. Oncoimmunology (2016) 0.75

Trial Watch: Proteasomal inhibitors for anticancer therapy. Mol Cell Oncol (2014) 0.75

Intermittent chemotherapy can retain the therapeutic potential of anti-CD137 antibody during the late tumor-bearing state. Cancer Sci (2014) 0.75

Polyfunctional Melan-A-specific tumor-reactive CD8(+) T cells elicited by dacarbazine treatment before peptide-vaccination depends on AKT activation sustained by ICOS. Oncoimmunology (2016) 0.75

Immunosuppressive γδ T cells foster pancreatic carcinogenesis. Oncoimmunology (2016) 0.75

The role of checkpoints in the treatment of GBM. J Neurooncol (2015) 0.75

Isobavachalcone inhibits the proliferation and invasion of tongue squamous cell carcinoma cells. Oncol Lett (2017) 0.75

Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med (2002) 19.60

Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08

Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 17.53

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 17.13

Tolerance, danger, and the extended family. Annu Rev Immunol (1994) 14.94

The danger model: a renewed sense of self. Science (2002) 13.85

PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol (2001) 12.26

Taking dendritic cells into medicine. Nature (2007) 11.82

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov (2004) 9.96

Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol (2002) 9.18

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol (2009) 8.68

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol (1998) 8.40

The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol (2007) 7.60

Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol (2012) 7.39

Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol (2004) 7.16

Immunogenic cell death in cancer therapy. Annu Rev Immunol (2012) 6.59

Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol (2010) 6.04

Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer (2007) 5.65

Fcgamma receptors: old friends and new family members. Immunity (2006) 5.60

Cancer immunotherapy via dendritic cells. Nat Rev Cancer (2012) 5.37

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol (2013) 5.36

TGFbeta signalling: a complex web in cancer progression. Nat Rev Cancer (2010) 5.27

Molecular mechanisms of cisplatin resistance. Oncogene (2011) 5.20

Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol (2009) 5.20

Transforming growth factor-beta in T-cell biology. Nat Rev Immunol (2002) 4.50

Complement regulators and inhibitory proteins. Nat Rev Immunol (2009) 4.46

An immunosurveillance mechanism controls cancer cell ploidy. Science (2012) 4.35

Toll-like receptors and cancer. Nat Rev Cancer (2008) 4.29

Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer (2012) 3.76

Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity (2013) 3.73

The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol (2009) 3.72

Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res (2012) 3.68

The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov (2012) 3.60

Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med (2013) 3.51

New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer (2002) 3.38

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol (2002) 3.30

TGF-beta released by apoptotic T cells contributes to an immunosuppressive milieu. Immunity (2001) 3.20

Complement and its role in innate and adaptive immune responses. Cell Res (2009) 3.07

Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors. Clin Cancer Res (2015) 2.97

Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol (2007) 2.92

Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother (2013) 2.80

Oncogenic stress sensed by the immune system: role of natural killer cell receptors. Nat Rev Immunol (2009) 2.44

Negative signaling by inhibitory receptors: the NK cell paradigm. Immunol Rev (2008) 2.40

The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol (2011) 2.36

The roles of TGFβ in the tumour microenvironment. Nat Rev Cancer (2013) 2.35

Phase-I clinical trial of monoclonal antibody in treatment of gastrointestinal tumours. Lancet (1982) 2.25

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol (2012) 2.14

Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat Rev Immunol (2004) 2.12

Decoding cell death signals in liver inflammation. J Hepatol (2013) 2.05

The GITR-GITRL interaction: co-stimulation or contrasuppression of regulatory activity? Nat Rev Immunol (2006) 2.03

Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol (2010) 2.00

Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology (2012) 1.88

Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood (2000) 1.84

Regulation of NK cell responsiveness to achieve self-tolerance and maximal responses to diseased target cells. Immunol Rev (2008) 1.74

First-in-class, first-in-human phase I results of targeted agents: highlights of the 2008 American society of clinical oncology meeting. J Hematol Oncol (2008) 1.70

A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. Blood (2012) 1.68

Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Clin Cancer Res (2013) 1.63

A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clin Cancer Res (2013) 1.60

Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia. Leuk Lymphoma (2012) 1.57

OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Res (2013) 1.57

Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology (2012) 1.51

Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. Clin Cancer Res (2013) 1.48

Targeting PD-1/PD-L1 interactions for cancer immunotherapy. Oncoimmunology (2012) 1.48

A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. Blood (2012) 1.46

Trial watch: Monoclonal antibodies in cancer therapy. Oncoimmunology (2013) 1.41

Trial Watch: Toll-like receptor agonists for cancer therapy. Oncoimmunology (2013) 1.35

Reassessing target antigens for adoptive T-cell therapy. Nat Biotechnol (2013) 1.34

Trial Watch: Monoclonal antibodies in cancer therapy. Oncoimmunology (2012) 1.34

Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies. Clin Cancer Res (2008) 1.34

Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology (2012) 1.33

Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology (2013) 1.31

Trial Watch: Anticancer radioimmunotherapy. Oncoimmunology (2013) 1.31

Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncoimmunology (2012) 1.30

Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone. Cancer Res (2008) 1.29

T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment. Cancer Immunol Immunother (2012) 1.19

Trial Watch: Immunostimulatory cytokines. Oncoimmunology (2012) 1.19

Trial Watch: Adoptive cell transfer immunotherapy. Oncoimmunology (2012) 1.18

Trial watch: Peptide vaccines in cancer therapy. Oncoimmunology (2012) 1.17

Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors. Oncoimmunology (2013) 1.16

Phase II clinical trial of a murine monoclonal antibody cytotoxic for gastrointestinal adenocarcinoma. Cancer Res (1985) 1.15

Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma. Int J Cancer (2007) 1.12

Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy. PLoS One (2013) 1.12

Identification of tumour-associated T-cell epitopes for vaccine development. Nat Rev Cancer (2002) 1.11

Cisplatin resistance associated with PARP hyperactivation. Cancer Res (2013) 1.11

A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma. Haematologica (2010) 1.10

Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology (2013) 1.09

Diversity of antigen-specific responses induced in vivo with CTLA-4 blockade in prostate cancer patients. J Immunol (2012) 1.09

Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy. Oncoimmunology (2014) 1.05

OX40 and CD30 signals in CD4(+) T-cell effector and memory function: a distinct role for lymphoid tissue inducer cells in maintaining CD4(+) T-cell memory but not effector function. Immunol Rev (2011) 1.05

Trial Watch: Peptide vaccines in cancer therapy. Oncoimmunology (2013) 1.04

A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia. Leuk Lymphoma (2010) 1.02

A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma. Br J Haematol (2012) 1.02

OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells. Oncoimmunology (2012) 1.01

The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4(+) T cells. Oncoimmunology (2013) 0.99

Molecular mechanisms of the antitumor effects of anti-CD20 antibodies. Front Biosci (Landmark Ed) (2011) 0.99

Understanding key assay parameters that affect measurements of trastuzumab-mediated ADCC against Her2 positive breast cancer cells. Oncoimmunology (2012) 0.97

Trial Watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology (2014) 1.49

Trial Watch:: Oncolytic viruses for cancer therapy. Oncoimmunology (2014) 1.22

Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy. Oncoimmunology (2014) 1.05

Trial Watch: Peptide vaccines in cancer therapy. Oncoimmunology (2013) 1.04

Trial Watch: Toll-like receptor agonists in oncological indications. Oncoimmunology (2014) 0.96

Trial Watch: Adoptive cell transfer for anticancer immunotherapy. Oncoimmunology (2014) 0.96

Trial watch: Immunostimulatory cytokines in cancer therapy. Oncoimmunology (2014) 0.95

Trial Watch: Lenalidomide-based immunochemotherapy. Oncoimmunology (2013) 0.94

Trial Watch: DNA vaccines for cancer therapy. Oncoimmunology (2014) 0.86